Clinical Trial

This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis

Withdrawn Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Due to the sponsor's adjustment of the research and development strategy for this clinical trial, this study was prematurely terminated, and no subjects were recruited for this study.
Summary
This is an open-label,early-stage exploratory clinical study to evaluate the safety and preliminary efficacy of GC012F CAR T cell injection in Multiple Sclerosis subjects.
Protocol Amendment History 5 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-04-05
notable Enrollment reduced: 15 -> 0 participants 2026-04-05
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-03-31
notable Primary completion moved earlier: 2027-02-10 -> 2026-03-25 2026-03-31
minor Completion moved earlier: 2029-12-10 -> 2026-03-25 2026-03-31
Trial Details
NCT Number NCT07364487
Lead Sponsor Huashan Hospital
Conditions Multiple Sclerosis
Start Date 2026-01-26
Primary Completion 2026-03-25 (estimated)
Study Completion 2026-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-03-30